Fig. 2: ZMYND8 drives trastuzumab plus pertuzumab resistance in HER2+ breast cancer in vitro.
From: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27
a, b Clonogenic growth of parental, ZMYND8 KO1 and KO2 HR6 cells treated with trastuzumab (Tras.), pertuzumab (Pert.), or trastuzumab+pertuzumab (Tras.+Pert.) for 6 days. Representative colony images (a) and quantification (b, n = 3). c, d Clonogenic growth of EV and ZMYND8 overexpressed BT474T cells treated with vehicle or trastuzumab+pertuzumab for 6 days. Representative colony images (c) and quantification (d, n = 3). e–h Growth of parental, ZMYND8 KO1 and KO2 organoids treated with vehicle, trastuzumab, pertuzumab, or trastuzumab+pertuzumab for 9 days. Representative organoid images (e, g) and organoid viability quantification (f, h, n = 3). Data from biological replicates represent mean ± SEM. P-value was determined by two-way ANOVA with Tukey’s test (b, d, f, and h). Scale bar, 200 μm. Source data are provided as a Source Data file.
